John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Future treatments Volume 17, supplement 5, novembre 2010

Figures

See all figures

Author
Centre national de référence des hépatites virales B, C et Δ, Laboratoire de virologie, Inserm U955, Hôpital Henri Mondor, Université Paris-Est, Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil

Numerous specific inhibitors of hepatitis C virus (HCV) are currently under development. The most advanced drugs in development to date are protease inhibitors and HCV replication inhibitors. The latter include nucleos(t)ide analogues, non nucleoside inhibitors of HCV RNA dependent-RNA polymerase, NS5A protein inhibitors and cyclophylin inhibitors. Two protease inhibitors, telaprevir and boceprevir, are currently under evaluation in combination with peginterferon-α and ribavirin, in Phase III trials. Triple combination should become soon the standard of care in HCV genotype 1 infected patients. In the next future, oral treatment of chronic hepatitis C may be envisaged, at least in subgroups of patients.